Every day the Cancer Center at CHOP strives for a future where targeted, precision medicine becomes the standard of care, therapeutic options are gentler with fewer side effects, and every cancer story ends in success. Thanks to Aldrich Foundation’s support, Dr. Richard Aplenc’s team has made significant strides in AML research, including supporting the largest proteomic study of any cancer to date and identifying new targets for immunotherapy.

In the year ahead, our continued support will drive Dr. Aplenc’s lab to complete this pioneering proteomic analysis, uncovering critical insights into pediatric AML and paving the way for breakthrough therapies that will redefine the future of care.